Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 17;59(1):e02136-20.
doi: 10.1128/JCM.02136-20. Print 2020 Dec 17.

COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory

Andrew M Borman  1   2 , Michael D Palmer  3 , Mark Fraser  3 , Zoe Patterson  3 , Ciara Mann  3 , Debra Oliver  3 , Christopher J Linton  3 , Martin Gough  3 , Phillipa Brown  3 , Agnieszka Dzietczyk  3 , Michelle Hedley  3 , Sue McLachlan  3 , Julie King  3 , Elizabeth M Johnson  3   2
Affiliations

COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory

Andrew M Borman et al. J Clin Microbiol. .

Abstract

COVID-19-associated pulmonary aspergillosis (CAPA) was recently reported as a potential infective complication affecting critically ill patients with acute respiratory distress syndrome following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with incidence rates varying from 8 to 33% depending on the study. However, definitive diagnosis of CAPA is challenging. Standardized diagnostic algorithms and definitions are lacking, clinicians are reticent to perform aerosol-generating bronchoalveolar lavages for galactomannan testing and microscopic and cultural examination, and questions surround the diagnostic sensitivity of different serum biomarkers. Between 11 March and 14 July 2020, the UK National Mycology Reference Laboratory received 1,267 serum and respiratory samples from 719 critically ill UK patients with COVID-19 and suspected pulmonary aspergillosis. The laboratory also received 46 isolates of Aspergillus fumigatus from COVID-19 patients (including three that exhibited environmental triazole resistance). Diagnostic tests performed included 1,000 (1-3)-β-d-glucan and 516 galactomannan tests on serum samples. The results of this extensive testing are presented here. For a subset of 61 patients, respiratory specimens (bronchoalveolar lavage specimens, tracheal aspirates, and sputum samples) in addition to serum samples were submitted and subjected to galactomannan testing, Aspergillus-specific PCR, and microscopy and culture. The incidence of probable/proven and possible CAPA in this subset of patients was approximately 5% and 15%, respectively. Overall, our results highlight the challenges in biomarker-driven diagnosis of CAPA, especially when only limited clinical samples are available for testing, and the importance of a multimodal diagnostic approach involving regular and repeat testing of both serum and respiratory samples.

Keywords: CAPA; COVID-19; SARS-CoV-2; biomarkers; candidemia; diagnosis; invasive pulmonary aspergillosis.

PubMed Disclaimer

References

    1. Schwartz IS, Friedman DZP, Zapernick L, Dingle TC, Lee N, Sligl W, Zelyas N, Smith SW. 2020. High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: a retrospective cohort study from Alberta. Can Clin Infect Dis 6:ciaa007. doi: 10.1093/cid/ciaa007. - DOI - PubMed
    1. Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, Lagrou K, Verweij PE, Van de Veerdonk FL, Gommers D, Spronk P, Bergmans DCJJ, Hoedemaekers A, Andrinopoulou ER, van den Berg CHSB, Juffermans NP, Hodiamont CJ, Vonk AG, Depuydt P, Boelens J, Wauters J, Dutch-Belgian Mycosis Study Group. 2018. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 6:782–792. doi: 10.1016/S2213-2600(18)30274-1. - DOI - PubMed
    1. Wauters J, Baar I, Meersseman P, Meersseman W, Dams K, De Paep R, Lagrou K, Wilmer A, Jorens P, Hermans G. 2012. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med 38:1761–1768. doi: 10.1007/s00134-012-2673-2. - DOI - PMC - PubMed
    1. Ku YH, Chan KS, Yang CC, Tan CK, Chuang YC, Yu WL. 2017. Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections. J Formos Med Assoc 116:660–670. doi: 10.1016/j.jfma.2017.06.002. - DOI - PubMed
    1. Verweij PE, Rijnders BJA, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, Calandra T, Clancy CJ, Cornely OA, Chiller T, Depuydt P, Giacobbe DR, Janssen NAF, Kullberg BJ, Lagrou K, Lass-Flörl C, Lewis RE, Liu PW, Lortholary O, Maertens J, Martin-Loeches I, Nguyen MH, Patterson TF, Rogers TR, Schouten JA, Spriet I, Vanderbeke L, Wauters J, van de Veerdonk FL. 2020. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med 46:1524–1512. doi: 10.1007/s00134-020-06091-6. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources